Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

Sarepta Therapeutics

Status and phase

Completed

Phase 1

Conditions

Encephalitis

Treatments

Drug: AVI-4065 Injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT00381433

AVI-4065-21c

Details and patient eligibility

About

AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065, which was designed to target HCV, is also a PMO; its ability to cross the blood-brain barrier is unknown. In this study, a single dose of AVI-4065 will be subcutaneously injected, and samples collected to determine if this drug crosses the blood-brain barrier. If it does, then additional investigations could be performed in people with severe forms of HCV disease in which the brain is affected.

Full description

Encephalopathy is a recognized consequence in some patients with HCV infection. In this study, a single dose of AVI-4065 will be subcutaneously injected, and samples collected to determine if this drug crosses the blood-brain barrier. If it does, then additional investigations could be performed in people with HCV disease in which the brain is affected.

Sex

Male

Ages

18 to 64 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adult males 18 years to 64 years of age;
Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range)
Signed and dated written informed consent form; and
Willing to participate in all study activities and all requirements, including effective contraception (viz., a double-barrier method) during the 7-day study surveillance period.

Exclusion criteria

Hematology, serum chemistry (exclusive of electrolytes), and urinalysis laboratory test values >2 times upper limits of normal or anemia (hemoglobulin <11 g/dL), leukopenia (total white blood count <3,000/µL or total neutrophils <1,500/ µL) or thrombocytopenia (platelets <100,000/µL). Electrolytes and coagulation values exceeding normal ranges are to be excluded.
Body Mass Index (BMI) >35.
Calculated creatinine clearance (by the Cockroft and Gault Formula) <70 mL/min, based on age and gender.
Positive HIV-1 or HIV-2 serology.
Positive HCV serology and/or positive plasma HCV-RNA status.
Positive HBsAg or HBcAb status.
Solid or hematopoetic organ transplant recipient.
Active illness or recent illness within 30 days of the first dose of study drug.
History of any of the following: brain injury, neoplasm, chronic or migraine headaches, cancer, meningitis or hydrocephalus.
Usage of any prescribed, over-the-counter or illicit drug(s) within 30 days of study drug administration. Use of herbal remedies and/or supplements at the discretion of the Investigator.
Unwilling to practice effective contraception during the study period.
Participation in any clinical interventional trial within the previous 6 months.
Positive drug urine screen.